Journal article

Retreatment with elbasvir, grazoprevir, sofosbuvir /- ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse

Timothy Papaluca, Marie Sinclair, Paul Gow, Stephen Pianko, William Sievert, Niranjan Arachchi, Karla Cameron, Scott Bowden, Jacinta O'Keefe, Joseph Doyle, Mark Stoove, Margaret Hellard, David Iser, Alexander Thompson

LIVER INTERNATIONAL | WILEY | Published : 2019

Abstract

INTRODUCTION: Despite highly effective direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection, some patients experience virological relapse. Salvage regimens should include multiple agents to suppress emergence of resistance-associated substitutions (RAS) and minimise treatment failure. The combination of sofosbuvir (SOF) and elbasvir/grazoprevir (ELB/GZR) ±ribavirin (RBV) is an effective retreatment strategy for HCV genotype (GT)1 and 4 infection. We hypothesised that SOF and ELB/GZR (±RBV) would also be an effective salvage regimen for DAA-experienced GT3 patients. METHODS: We evaluated the efficacy and safety of SOF/ELB/GZR ± RBV in DAA-experienced participa..

View full abstract